In contrast to LDLR-pathway drugs, genetically predicted LPL pathway targeting scaled on apoB levels have heterogeneous associations with CAD, suggesting that the association of the LPL pathway with CAD is not entirely explained by apoB lowering6. This evidence concerns the gene LPL and coronary artery disorder.